ReviewExploration of targeted anti-tumor therapy2026
Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics.
Jovana Zivanovic et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.